From 3 to 6 June 2024, Inaphaea’s Head of Strategic Development, Dr Andrew Carnegie and our Scientific Consultant, Dr Mark Eccleston attended the BIO International Convention in San Diego with our partners Inspiralis and Physiomics.
To broaden Inaphaea’s reach and engage with potential customers globally, our team attended BIO to discuss Inaphaea’s capabilities with businesses from the US and around the world. We highlighted our PDC models, available in both 2D and 3D formats, along with our immuno-oncology assays.
BIO 2024
Commenting on the event, Andrew said: “Looking back at Bio in San Diego, I have to give a big thank you to the organisers. From the smooth partnering system, the excellent networking during the event and the multitude of evening events all offering superb networking opportunities this is a gold standard event. I am looking forward to following up with all the old and new friends we met last week. It is always fun to say hello to somebody who lives near to you in the UK over a drink at a baseball stadium in San Diego. The take home message for us is that our Immune-Oncology capabilities are being offered at the right time to the right companies, which will drive us forward through 2024 and beyond.”
During BIO, Andrew also spoke to BioPharm International’s Science Editor, Feliza Mirasol about the role of a translational CRO and of PDC models in drug discovery. In the interview, Andrew outlines trends in the R&D analytical space and discusses analytical advances being made to cut short timelines for discovering new drug candidates.
The article and interview can be viewed here.
